Biotechnology Analysts Duncan, Stavropoulos and Kluska, along with Dr. Orchard, Professor-Pediatrics Dept at the University of Minnesota Medical School, discuss current and investigational treatments for Lysosomal Storage Disorders, including Denali Therapeutics’ (DNLI) enzyme transport vehicle (ETV) technology, including recent findings for DNL310, on an Analyst/Industry conference call to be held on February 3 at 12 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNLI:
- Cantor Fitzgerald biotech analysts to hold analyst/industry conference call
- Denali Therapeutics initiated with an Outperform at SVB Securities
- Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial
- Centogene, Denali extend observational study on Parkinson’s disease genetics
- Denali Therapeutics announces 2023 milestones